Meeting deadlines in a bioanalysis laboratory can be a big challenge. Older, less sensitive and less reliable LC-MS systems make it even more difficult. Even the disruption caused by the installation and validation can be disconcerting and delay decisions. Does this sound familiar?
Tags
Overcoming uncertainty in your PFAS analysis
Just like gum on the bottom of a shoe, the existence of per- and poly-fluorinated alkyl substances (PFAS) in our environment is a sticky one. If you’re in the field of environmental testing, then you’re all too familiar with the threat these substances have on public health. While we have learned a lot about them over the years, there is still much more to understand. With the right detection methods, we can gather the information we need to empower us to make informed decisions on reducing the risks they impose.
6 Signs it’s time for a new vendor
A lab’s success depends on many factors from instrument quality to efficient operations, including being partnered with the right vendor. A vendor is more than just a supplier. They should provide you with a high-level quality of support in maximizing the lifespan and performance of your systems, reducing downtime, enhancing ROI and more. How do you know if you’re partnered with the right one? Here are six signs it might be time to find someone new.
Selecting an LC-MS system for quantitation of pharmaceutical drug development
We understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created a solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options.
Nitrosamines: Where are we now?
Nitrosamines are a large group of N-nitroso compounds that share a common functional N-N=O group. They are produced by a chemical reaction between a nitrosating agent and a secondary or tertiary amine. Back in 2018, nitrosamines suddenly found themselves in the spotlight when they were unexpectedly detected in medications for high blood pressure. Since then, they have been found in several other prescription medications, including those for heartburn, acid reflux and diabetes, resulting in manufacturers recalling some common medications.
Celebrating customer experience: Insights from SCIEX leaders
Introduction Customer Experience Day (CX Day) is a special occasion for SCIEX, celebrated every first Tuesday in October. It’s a day dedicated to recognizing the incredible value of our customers and the relentless dedication of our associates who strive to make...
PFAS analysis in food: a robustness study in sensitivity and stability
The combination of per- and polyfluoroalkyl substances (PFAS) testing, trace-level regulatory requirements and complex MS applications can be intimidating. In a recent webinar, now available on demand, SCIEX PFAS expert Craig Butt demonstrated how the new SCIEX 7500+ system can help make PFAS testing easier.
Your success and voice go a long way!
At the heart of everything we do is ensuring that your workflows and team are empowered to achieve optimal results with your SCIEX instruments, software, consumables, and services. Every interaction with SCIEX is designed to support your success through the dedication...
FDA’s final rule on LDTs: what does it mean for clinical laboratories?
On April 29, 2024, the U.S. Food and Drug Administration (FDA) announced a final rule regulating laboratory developed tests (LDTs) as in vitro diagnostic devices (IVDs) under the Federal Food, Drug and Cosmetic Act (FD&C Act). This rule amends FDA’s regulations to state that in vitro diagnostic tests “manufactured” by clinical laboratories fall within the scope of the FDA regulatory oversight and is poised to dramatically shift the way clinical diagnostic laboratories in the United States develop and offer LDTs in the future. Read this blog post for a basic overview of the scope, intent and implications of this final rule, including the regulatory requirements, exceptions and timeline for implementation.
LC-MS system replacement: Are you ready?
Meeting deadlines in a bioanalysis laboratory can be a big challenge. Older, less sensitive and less reliable LC-MS systems make it even more difficult. Even the disruption caused by the installation and validation can be disconcerting and delay decisions. Does this sound familiar?
An overview: LC-MS analysis of targeted protein degraders and their metabolites
Targeted protein degraders (TPD) are a relatively new therapeutic modality that opens the potential to target disease-causing proteins. These disease-causing proteins have been highly challenging for traditional small-molecule therapeutics to treat, making TPDs an exciting new therapeutic modality.
Standard addition workflow – for quantification and calculating background levels
The method of standard addition is a quantitative analysis approach used in situations where matrix effects from complex samples contributes to the analytical signal. This makes it impossible to compare the analytical signal between sample and standard using a...
How do I define the experimental design (the metadata) for my SWATH acquisition study within the OneOmics suite? What are the requirement for replicates?
In quantitative Omics research, the goal is to understand which analytes (protein or metabolite) are perturbed between experimental conditions; therefore we carefully design our studies to explore these questions. The algorithms used within the Assembler application...
Downloading results from SCIEX Data Store or BaseSpace
Once your data processing sessions have completed, the results files are saved back to either SCIEX Data Store or BaseSpace. These can be downloaded from the cloud to your desktop for additional analysis. Please see these community posts to learn more: Explaining the...
What are my normalization options in MarkerView software and when should I use them?
In an LC-MS experiment there are multiple sources of variance that can confound the quality of your results. This variation can be biological e.g. differences between treated and control groups, but can also be non-biological, usually from small variations in...
Quickly compare identification results from ProteinPilot software
When a ProteinPilot Software search is complete, a ProteinPilot report is generated that contains all the false discovery rate (FDR) analysis information. More information on using the large and small ProteinPilot reports can be found here When doing method...
Computing protein confidence with improved accuracy by reassessing peptide confidence during protein grouping
ProteinPilot software 4.0 and higher releases include a new method for calculating protein confidences that improves reliability at the end of protein lists. Figure 1 shows a simulated example that demonstrates how more accurate protein confidence is computed. Figure...
Top questions about the exposome of PFAS revealed
According to the CDC, the exposome is “the measure of all the exposures of an individual in a lifetime and how those exposures relate to health.”
Breaking down the SCIEX Triple Quad™ 7500 LC-MS/MS System – QTRAP® Ready
Sensitivity and robustness carry different meanings in the world of mass spectrometry. Generally, sensitivity refers to an instrument’s ability to achieve lower limits of detection (LOD). Robustness, on the other hand, refers to an instrument’s ability to consistently...
The honey sting
As a consumer it’s hard for me not to feel inundated with claims that our food is “all-natural” or “chemical-free” or that we should buy certain “superfoods” for their health benefits. We read labels and trust that the product we are buying is what we are truly...
The top 5 questions to ask when investing in accurate mass technology for forensic toxicology workflows
Are you considering the purchase of a high-resolution accurate mass (HRAM) instrument for your forensic toxicology lab? To help ensure you invest in a solution that ideally meets your needs, ask yourself the following key questions. 1. How do I ensure my results...
Innovation that’s blasting through limitations in explosive detection
Mass spectrometry’s important role in identifying explosives The need for rapid explosive detection is now an unfortunate reality. The remit is multifaceted. The first is for preventative purposes, to protect us from any threat to life. The second is in the...
A new generation of therapeutic modalities
There are over 7,000 genetic diseases that could potentially be cured using gene therapy. Rare metabolic diseases, autoimmune disorders, cardiovascular disease and cancers are some of the top disease classes that can be addressed with gene therapies. With over 1,000...
Enhancing Biologics with CESI-MS Characterization
Comprehensive characterization of a biologic requires analysis at both the intact and digest levels, but these analyses can be complex and cumbersome. For example, with conventional liquid chromatography separations, researchers are often left with limited information...
Full, partial and empty capsid ratios for AAV analysis: What’s the big deal?
For many of you working to develop gene therapy drugs, you know that the time to market the drug is critical. Because gene therapeutics cure diseases by targeting specific genes, it is a constant race to see who develops the drug first. Unlike other classes of drugs where multiple medications can be used to treat a disease, whoever is first to develop a gene therapy drug wins.
Accurate mass LC-MS/MS for PFAS analysis without needing a blockbuster budget
If you’ve been following our recent blogs, you’ve probably seen quite a bit on how per- and polyfluoroalkyl substances (PFAS) are shaking up both the food and environmental industry. Even if you’ve not been following our blogs, you’ve probably seen a lot of media...
A rising star in food allergen research: proteomics of shellfish allergen
It’s important to know what you’re eating, especially if you suffer from a food allergy.
About 220 million people worldwide live with a food allergy.1 These numbers, along with the complexity and severity of conditions, continue to rise. In America, there are about 32 million food allergy sufferers—5.6 million of those are children under the age of 18.2.2 That’s 1 out of every 13 children, or about 2 in every classroom. From a financial perspective, the cost of food allergy childcare for US families is up to $25 billion
Routine cannabis screening is here. Will your lab reap the benefits?
Fast, accurate, and robust solution for routine commercial cannabis testing
As the world debates cannabis legalization for therapeutic applications and recreational use, the trends are shifting. Medicinal use of cannabis is legal in an increasing number of countries worldwide, including 33 states and the District of Columbia in the United States. Uruguay was the first country in the world to legalize the sale, cultivation, and distribution of cannabis in 2013. In the United States, Washington and Colorado were the first to fully legalize cannabis in 2012. By the end of 2019, 10 states have legalized recreational use for adults over the age of 21, with 64% of Americans favoring the move
Keep up with fentanyl and its analogs: Failure to do so is not an option.
Fentanyl is one of the most well-known synthetic opioids that has been in the spotlight lately—and not for good reasons. The World Drug Report 2019 reveals that there have been more than 47,000 opioid overdose deaths in the United States in 2017. This is an increase...
Hemp, marijuana, CBD and THC: what’s the difference?
Cannabis refers to a genus of flowering plants originating from Asia.1 It's also an umbrella term that includes both marijuana plants and hemp plants, among others. With the flurry of legalization across the United States, CBD and THC derived products have been thrown...
Mysterious Vaping Detectives Part 2
In our last blog, I gave you some current highlights about the mysterious vaping illness that was making headlines (and still is). The condition now known as, e-cigarette or vaping, product use-associated lung injury (EVALI) has sickened thousands and killed 57...